<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BOSENTAN</span><br/>(bo-sen'tan)<br/><span class="topboxtradename">Tracleer<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">vasodilator</span>; <span class="classification">endothelin receptor a antagonist</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>62.5 mg, 125 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Bosentan is a potent endothelin A receptor antagonist. Endothelin is a peptide with potent vasoconstrictor activity implicated
         in the pathogenesis of hypertension, CHF, and renal failure. Bosentan is a potent dilator of pulmonary vascular beds in patients
         with primary pulmonary hypertension, although it is not selective for pulmonary vasculature alone.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bosentan vasodilates the pulmonary vasculature thus reducing pulmonary hypertension.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of pulmonary arterial hypertension (PAH).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bosentan; pregnancy (category X), lactation; concomitant administration with cyclosporine or glyburide.
         Safety and efficacy in pediatric patients have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver disease or reduces hepatic blood flow; severe hypertension.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pulmonary Arterial Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 62.5 mg b.i.d., may titrate up to 125 mg b.i.d.<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>If LFTs &gt;3 and <img src="../images/special/lesserorequal.gif"/>5 <small>x</small> upper limit of normal (ULN) reduce dose
               and monitor LFTs q2wk. If LFTs return to normal may continue treatments. If LFTs &gt;5 and <img src="../images/special/lesserorequal.gif"/>8
               <small>x</small> ULN, discontinue and monitor LFTs q2wk. If LFTs return to normal, may restart drug cautiously. If LFTs &gt;8
               <small>x</small> ULN, discontinue and do not restart.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not administer unless liver function tests have been performed and the patient has been determined to have adequate liver
            function.
         </li>
<li>Give in the morning and evening with or without food.</li>
<li>Do not administer to anyone also receiving glyburide or cyclosporine.</li>
<li>Store in a tightly closed container at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flushing, lower limb edema, fatigue. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache.</span>
<span class="typehead">CV:</span> Hypotension, palpitations, edema. <span class="typehead">GI:</span>
<span class="speceff-common">Abnormal AST, ALT</span>, dyspepsia. <span class="typehead">Respiratory:</span>
<i>Nasopharyngitis</i>. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">macrolide antibiotics</span>, <b>cimetidine,</b>
<b>cyclosporine,</b>
<b>fluoxetine,</b>
<b>ketoconazole</b> may increase bosentan levels; may decrease concentrations of <b>simvastatin,</b>
<b>tacrolimus;</b>
<b>carbamazepine,</b>
<span class="classification">oral contraceptives</span>, <b>phenytoin,</b>
<b>rifampin</b> may decrease bosentan levels; <b>glyburide</b> may cause increase LFTs and lack of hypoglycemic effects. <span class="typehead">Herbal:</span>
<b>Ephedra,</b>
<b>Ma Huang</b> may antagonize antihypertensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% bioavailability. <span class="typehead">Peak:</span> 35 h. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized by CYP3A4 and CYP2C9 to 3 metabolites, one is active. <span class="typehead">Elimination:</span> Primarily excreted in bile. <span class="typehead">Half-Life:</span> 5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor LFT (ALT, AST, bilirubin) within 3 d of initiating treatment and q2wk thereafter. Use same monitoring schedule
            following discontinuation and reintroduction of bosentan. Monitor Hgb at periodic intervals.
         </li>
<li>Report immediately ALT &amp; AST elevations accompanied by S&amp;S of liver injury (jaundice, nausea, vomiting, fever, abdominal pain,
            lethargy or fatigue) or bilirubin <img src="../images/special/greaterorequal.gif"/>2 <small>x</small> ULN.
         </li>
<li>Concurrent drugs: Monitor lipid profile in patients receiving lipid-lowering statin drugs; the dose of the statin drug may
            need to be adjusted. Monitor PT/INR in patients receiving oral anticoagulants, especially when bosentan is added or withdrawn
            and periodically during concurrent therapy; adjustments in the anticoagulant may be necessary.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use a barrier form of birth control in addition to oral, injected, or implanted contraceptives while taking bosentan.</li>
<li>Contact physician immediately if you think you are pregnant.</li>
<li>Do not breast feed while using this drug without consulting physician.</li>
<li>Do not take glyburide while receiving bosentan. Contact your physician for an alternative drug for control of blood glucose.</li>
<li>Do not use any OTC medications, vitamins, or herbal supplements without clearance from your physician.</li>
<li>Notify physician immediately if you experience any of the following: dark-colored urine, pale stools, nausea and vomiting,
            loss of appetite, stomach pain, yellow skin or eyes, fast or pounding heartbeat, swelling in your ankles or feet.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>